This observational study will evaluate the safety, efficacy, characteristics of patients, characteristics of physicians and quality of life in patients who are prescribed OZURDEX® as treatment for non-infectious uveitis of the posterior segment of the eye in France.
Study Type
OBSERVATIONAL
Enrollment
246
Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
CHU Amiens
Amiens, France
IOP Institut Ophtalmologique de Picardie
Amiens, France
Percentage of Participants with Best Corrected Visual Acuity (BCVA) ≥15 Letters
Time frame: 2 Months
Percentage of Participants with a Gain (Improvement) in BCVA of at Least 15 Letters from Baseline
Time frame: Baseline, Months 6 and 18
Change from Baseline in BCVA
Time frame: Baseline, Months 2, 6 and 18
Change from Baseline in Vitreous Haze Score Using a 5-Point Scale
Time frame: Baseline and Months 2, 6 and 18
Change from Baseline in Macular Thickness
Time frame: Baseline, Months 2, 6 and 18
Percentage of Participants Categorized by Comorbidities (Diseases Associated with Inflammation, Other Ophthalmic Diseases, General Comorbidities)
Time frame: 18 Months
Change from Baseline in the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ25) Score Using a 25 Item Questionnaire
Time frame: Baseline, Months 2 and 18
Number of Repeat Treatments with OZURDEX® and Other Drugs
Time frame: 18 Months
Time Between Repeat Treatments with OZURDEX® and Other Drugs
Time frame: 18 Months
Percentage of Participants with Adverse Events (AEs)
Time frame: 18 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Centre Rétine Gallien
Bordeaux, France
Hopital Pellegrin
Bordeaux, France
CHI de Créteil
Créteil, France
CHU Dijon
Dijon, France
Centre Pôle Vision Val d'Ouest
Écully, France
Hopital Claude Huriez
Lille, France
Hopital De La Croix Rousse
Lyon, France
Clinique Monticelli
Marseille, France
...and 11 more locations